ArticleJournal of medical case reports2026
Ovarian carcinosarcoma (malignant mixed Müllerian tumor, MMMT) in a premenopausal woman: a diagnostic challenge-a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOvarian carcinosarcoma, also known as malignant mixed Müllerian tumor (MMMT), is a rare and highly aggressive gynecologic malignancy characterized by the presence of both epithelial and mesenchymal components. It predominantly affects postmenopausal women, and its occurrence in premenopausal patients is uncommon. Due to its rarity, optimal management strategies remain poorly defined. CASE PRESENTATION: We report the case of a 33-year-old premenopausal Han Chinese woman diagnosed with ovarian carcinosarcoma who underwent complete cytoreductive surgery followed by platinum-based chemotherapy. Germline BRCA1/2 mutation testing and homologous recombination deficiency (HRD) assessment were performed and yielded negative results. Following a favorable response to chemotherapy, maintenance therapy with Olaparib was initiated as an individualized, off-label approach after multidisciplinary team discussion and with full patient-informed consent. Sustained disease control was observed during a 46-month follow-up period, without significant treatment-related adverse events.
conclusionThis case highlights the importance of accurate diagnosis and optimal surgical and systemic management in ovarian carcinosarcoma. While maintenance therapy with Olaparib was used in an individualized, off-label setting despite negative BRCA and HRD testing, this approach should not be generalized. Further studies are needed to better define the role of targeted therapies in this rare and aggressive tumor subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.